Ernexa Therapeutics Inc. (ERNA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.95 (-1.01% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ERNA ranks #705 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).
Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $26.1M in revenue (+4383.4% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.9 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ERNA currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.19) and Max Pain ($2.05) forces dealer call-delta covering toward $49.61.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Ernexa Therapeutics Inc. (ERNA) slipped -1.01% to $1.95, trading at 2% of its 52-week range ($1.84 – $47.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief Ex
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4383.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ERNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ERNA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Ernexa Therapeutics Inc. (ERNA) ranks #705 by composite RQD confidence (33/100, grade E) and #974 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, ERNA leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ERNA at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ERNA
ACTIVE
Ernexa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.01% | $3.2M | Benchmark Subject |
| EOCN Eocene Ltd. | E | 34/100 | — | — | -35.0% | -7.54% | $3.2M | /eocn-vs-erna → |
| CMND Clearmind Medicine Inc. | D | 47/100 | — | — | — | -1.27% | $3.2M | /cmnd-vs-erna → |
| SXTP 60 Degrees Pharmaceuticals Inc. | D- | 38/100 | — | 22.3% | -35.0% | -3.65% | $3.3M | /sxtp-vs-erna → |
| ONCO Onconetix Inc. | E | 30/100 | — | 77.6% | -35.0% | -3.24% | $3.3M | /onco-vs-erna → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported GAAP revenue of $26.1M (+4383.4% vs. FY2024 revenue of $582.0K , and +38272.4% cumulative change since FY2023) , GAAP net income of -$14.1M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (+56.5% YoY). On the balance sheet, ERNA closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $26.1M | -$14.1M | -$7.0M | -$7.1M | $5.8M | — |
| FY2024 (FY) | 2024-12-31 | $582.0K | -$44.5M | -$15.8M | -$16.2M | $5.3M | — |
| FY2023 (FY) | 2023-12-31 | $68.0K | -$21.7M | -$20.4M | -$20.4M | — | — |
As of 2026-11-03, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.95 (-1.01% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ERNA ranks #705 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).
Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $26.1M in revenue (+4383.4% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ERNA last traded at $1.95 (-1.01% on volume of 9,001 shares), positioning the stock -38.87% below its 50-day simple moving average ($3.19) and -72.42% below its 200-day simple moving average ($7.07). Across its 52-week range of $1.84 to $47.25, ERNA sits at the 0.2% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).
Ernexa Therapeutics Inc. (ERNA) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.95 (-1.01% 1D, market capitalization $3.2M).
Ernexa Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The source does not describe its products, customers, or revenue model. Reported revenue is — for FY 2025, $0.6M for FY 2024, and $0.1M for FY 2023, . Its news flow references ERNA-101 and a cell therapy plus immune treatment in animal studies.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported $26.1M in annual revenue (up from $582.0K in FY2024, +4383.4% YoY) and -$14.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($68.0K revenue, -$21.7M net income) through FY2025, ERNA scaled operating cash flow to -$7.0M and free cash flow to -$7.1M, backed by $5.8M in total assets against $0 in total debt.
An investor should note that the absence of mapped dependencies means no ripple effects can be traced from this source.
Real-time company headlines, analyst actions, and sector developments for Ernexa Therapeutics Inc. (ERNA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief Ex
The stock shows a recent 6.57% price gain and news flow on ERNA-101 animal results and a Flash Talk selection.. When you look under the hood at ERNA, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $47.25. My 12M target is $2.50.
Both sides have a point here — ERNA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Fading this rally in ERNA at $1.97. The RQD score of 33 (grade E) is driven by ROIC of -35%, 0% FCF yield, and a whale flow score of 3 out of 20.. With a beta of 1.0 and the stock sitting at $1.97 (52-wk range $1.84–$47.25), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).